Kornimate/medical-research-clean huggingface dataset:
swallow exercise as prophylaxis of dysphagia after radiotherapy

Conditions: Head and Neck Cancer

Summary: background: dysphagia is a common side effect after radiotherapy for haed and neck cancer patients. it may be worsened by immobility of the throat during tube feeding. hypothesis: exercises may prevent or reduce late dysphagia. method: phase i study to identify the tolerated intensity of exercises and establish the method of measuring training intensity and dysphagia measurement. endpoint: objective dysphagia using vf and feesst. the hn swallowing and hn pain endpoint of eortc h\&n35 questionnaire. weight loss, duration of tube feeding.


Eligibility criteria:
inclusion criteria: * head and neck cancer * planned curative radiotherapy * planned irradiation of level ii+iii lymph nodes \>46 gy * \>=18 y * speaks and reads danish * no previous surgery to the head and neck area except biopsies exclusion criteria: -

Keywords: head and neck cancer radiotherapy dysphagia exercise deglutition randomized controlled trial quality of life tube feeding
association between peripheral artery stiffness and cardiovascular disease

Conditions: Arteriosclerosis

Summary: arterial pulse wave velocity (pwv) is strongly correlated with atherosclerosis, and the pwv of carotid or femoral artery could predict the severity of arterial atherosclerosis. because the measurement of pwv is noninvasive, it would serve as a good clinical and screen marker to evaluate the extent of atherosclerosis. the study uses self-made pwv measurement device to investigate the correlation of the pwv in the high cardiovascular risk population, and compare it with normal population.


Eligibility criteria:
inclusion criteria: * patients with a high risk for cardiovascular disease

Keywords: pulse wave velocity cardiovascular disease
use of pediatric size phlebotomy tubes in adult critically ill patients to reduce red blood cell transfusions

Conditions: Anemia

Summary: this study will evaluate the hypothesis that the use of pediatric size phlebotomy tubes reduces red blood cell (rbc) transfusions in adult intensive care unit (icu) patients compared with the use of adult size tubes.


Eligibility criteria:
inclusion criteria: * new admission to the medical or transplant icu at memorial hermann hospital in houston * icu admission hemoglobin level of at least 7 g/dl. the icu admission hemoglobin will be the most recent hemoglobin value available at the time of screening for inclusion in the study. * randomization is expected within 12 hour of admission to the icu exclusion criteria: * clinical bleeding. defined as menstrual bleeding, bleeding leading to a change in the frequency of hemoglobin monitoring or to an order for a medication, transfusion, procedure, or consultation intended to prevent or treat bleeding. * known hemolytic disorder (e.g. sickle cell disease, hereditary spherocytosis, autoimmune hemolytic anemia) * bone marrow disorder (e.g. aplastic anemia, marrow infiltration disorder, chemotherapy within the last 8 weeks) * jehovah's witnesses * patient is comfort care measures only * refractory shock: mean arterial blood pressure below 60 mmhg despite maximal doses of 3 vasopressors. maximal dose of vasopressors are as follows: norepinephrine 70 mcg/min; vasopressin 0.04 units/min; epinephrine 35 mcg/min; dopamine 20 mcg/kg/min; phenylephrine 350 mcg/min * severe acidosis: potential of hydrogen (ph) below 7 in more than one arterial blood gas within 24 hours of icu admission in the absence of diabetic ketoacidosis surgical admission diagnosis * pregnancy * current prisoner

Keywords: blood transfusion
gp induction chemotherapy us tpf adjuvant chemotherapy combined with ddp concurrent chemoradiotherapy in the treatment of locally advanced npc

Conditions: Locally Advanced Nasopharyngeal Carcinoma

Summary: through randomized controlled phase iii multicenter clinical trials, gp induction chemotherapy vs tpf regimen adjuvant chemotherapy combined with ddp concurrent chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma: the efficacy, toxicity and quality of life, and further improvement survival rate and improve the quality of life.


Eligibility criteria:
inclusion criteria: 1. in the newly diagnosed patient, no radiotherapy or chemotherapy was performed before the start of the clinical trial. 2. pathologically confirmed as non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated, ie who type ii or iii). 3. iii, iva patients (ajcc version 8 staging). 4. male or non-pregnant women. 5. age ≥ 18 and \< 70 years old. 6. functional status: karnofsky scale (kps) \> 70. 7. white blood cells (wbc) ≥ 4 × 109. /l, hemoglobin (hgb) ≥ 90 g / l, platelets (plt) ≥ 100 × 109 / l (or within the normal range of the laboratory) 8. liver function: alanine aminotransferase (alt), aspartate aminotransferase (ast) ≤ 1.5 times the upper limit of normal (uln); total bilirubin ≤ 1.5 × uln. 9. renal function: creatinine clearance ≥ 60ml / min or serum creatinine ≤ 1.5 × uln. 10. the patient has signed an informed consent form. exclusion criteria: 1. the pathological type is who's keratinized squamous cell carcinoma or basal squamous cell carcinoma. 2. age ≥ 70 years old or \< 18 years old. 3. treatment is palliative. 4. previous history of malignant tumors, well-treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ outer. 5. women during pregnancy or lactation (pregnant women should be considered for women of childbearing age; effective contraception). 6. previously received radiation therapy (if non-melanoma skin cancer and previous lesions are outside the target area of radiotherapy, then except). 7. primary and cervical metastatic lesions received chemotherapy or surgery (except for diagnostic treatment). 8. with other serious diseases, it may bring greater risk or affect the compliance of the test. for example: no need for treatment stable heart disease, kidney disease, chronic hepatitis, control of unsatisfactory diabetes (fasting blood glucose \> 1.5 × uln),and mental illness.
articular sonography: healthy subjects versus rheumatoid arthritis patients

Conditions: Disorders of Synovium, Multiple Sites; Disorders of Subchondral Bone, Multiple Sites; Disorders of Cartilage, Hand Joints; Arthritis, Rheumatoid; Healthy People

Summary: the purpose of this study is to establish the normality of sonographic synovial measures in joints more affected in rheumatoid arthritis patients and establish, in those joints, a sonographic value of synovium predictive of rheumatoid arthritis.

rheumatoid arthritis (ra) is a chronic inflammatory, systemic and auto-imune disorder affecting primarily the joints. in ra, inflammatory synovium causes destruction of cartilage, erosion of the adjacent bone and ultimately loss of function of the affected joint. newer imaging techniques, such as ultrasound (us), have shown promise in evaluation of ra. many us scoring system have been used to classify and quantify the synovium, effusion, erosion and cartilage for assessing and monitoring ar. however, its use is considered problematical because there are very few data on normal joints and, at this point, there is no clear definition of excess amount of synovium in normal people.

Eligibility criteria:
inclusion criteria: * no articular disease (healthy group) * establish rheumatoid arthritis (ra group) exclusion criteria: * diabetes * hypothyroidism- hemophilia * pregnancy * previous septic arthritis * previous articular surgery * symptomatic osteoarthritis * no superimposed collagenoses (ra group)
the efficiency of dry needling and cold spray-stretching treatments

Conditions: Myofascial Pain Syndromes; Myofascial Trigger Point Pain

Summary: a prospective randomized single-blind study included 60 patients aged 18-65 years who have mps with active triger points in the upper trapezius muscle. patients were randomized into two treatment groups as dry needling (dn) and cold spray-stretching. both treatment groups received 1 treatment per week and totally 3 sessions. evaluation parameters were pain level assessed by visual analog scale (vas) and algometer, neck range of motion angles, functional level assessed by neck disability index (ndi). the effects of the treatments on active trigger points were evaluated by semg and us histogram. all parameters were evaluated at the beginning of the treatment and after 3 sessions of treatment. algometer and semg were performed also before and after the 1st and 3rd sessions.

objective: to compare the efficacy of dry needling and cold spray stretching treatments using surface electromyography (semg) and ultrasound (us) in the treatment of patients with myofascial pain syndrome (mps) with active trigger point (trp) in the upper trapezius muscle. material and methods: a prospective randomized single-blind study included 60 patients aged 18-65 years who have mps with atp in the upper trapezius muscle. patients were randomized into two treatment groups as dry needling (dn) and cold spray-stretching. both treatment groups received 1 treatment per week and totally 3 sessions. evaluation parameters were pain level assessed by visual analog scale (vas) and algometer, neck range of motion angles, functional level assessed by neck disability index (ndi). the effects of the treatments on atp were evaluated by semg and us histogram. all parameters were evaluated at the beginning of the treatment and after 3 sessions of treatment. algometer and semg were performed also before and after the 1st and 3rd sessions.

Eligibility criteria:
inclusion criteria: * neck and / or back pain for at least 3 months, * pain level\> 3 in vas measurement * presence of active trigger point in upper trapezius muscle exclusion criteria: * cervical radiculopathy * history of neck and / or shoulder surgery * dry needling treatment in the neck and / or shoulder area in the last 1 month * coagulation disorder and / or use of anticoagulant therapy * migraine or dementia * pacemaker * needle phobia * allergies to the substances in the coolant spray to be used

Keywords: cold spray dry neddling histogram trigger point
adjuvant hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer

Conditions: Locally Advanced Malignant Neoplasm; Gastric Cancer

Summary: the purpose of this study is to determine safety and feasibility of adjuvant hyperthermic intraperitoneal chemotherapy (hipec) with mitomycin and cisplatin in patients with locally advanced gastric cancer undergoing standard surgical resection. patients will be treated with hipec using a single dose of mitomycin 15mg/m2 and cisplatin 50mg/m2 at 41-42 c for 90 minutes, during the definitive surgical resection for gastric cancer. hipec will be performed after resection but before anastomosis.

treatment plan: patients undergoing definitive resection for gastric cancer and meeting the eligibility criteria will be treated with hipec using a single dose of mitomycin 15mg/m2 and cisplatin 50mg/m2 at 41-42 c for 90 minutes. hipec will be performed after resection but before anastomosis. both cisplatin and mitomycin are commercially available chemotherapeutic agents and will be obtained as marketed drugs. outcome measures: patients will be followed for 90 days following surgery. all postoperative complications will be recorded and graded according to the modified clavien-dindo classification. schedule for follow up: trial-related patient assessments will be performed daily while the patient remains in the hospital for postoperative care, and then during postoperative clinic visits. the final postoperative clinic visit for evaluation of study outcomes and complications should occur between postoperative days 90 and 95 to allow for a cumulative assessment of the patient's perioperative complications, if any.

Eligibility criteria:
inclusion criteria: 1. patients aged 18-75 with biopsy-proven gastric adenocarcinoma 2. tumor clinically staged t3 or t4 and/or nodes staged clinically positive 3. ecog performance status \< 2 exclusion criteria: 1. distant metastases 2. peritoneal carcinomatosis 3. synchronous malignancy 4. tumors at the gastroesophageal junction 5. recurrent gastric adenocarcinoma 6. creatinine \>/= 1.5 7. bilirubin \>/= 2 8. inr \>/= 2 9. allergy to drugs included in the treatment plan 10. pregnancy 11. contraindication to major surgery
safety and efficacy evaluation of the monopolar radiofrequency device for the improvement of facial wrinkles

Conditions: Facial Wrinkles; Anti-Aging; Wrinkles and Rhytides; Wrinkles Such As Nasolabial Folds; Wrinkles

Summary: the goal of this clinical trial is to evaluate the safety and efficacy of the monopolar radiofrequency therapy device developed by classys inc. for improving facial and periorbital wrinkles. this is a prospective, multicenter, evaluator-blinded, randomized, parallel-controlled, non-inferiority clinical trial. the main questions the study aims to answer are: does the monopolar radiofrequency device improve the appearance of facial and periorbital wrinkles? is the safety profile of the monopolar radiofrequency device acceptable? researchers will compare the investigational device to the thermage cpt system (solta medical co., ltd.) to see if the monopolar radiofrequency device is non-inferior in terms of wrinkle improvement. participants will: undergo a single treatment session with either the investigational device or the control device. be followed up for a period of 3 months to assess wrinkle improvement and safety outcomes. the primary outcome will be the improvement in facial and periorbital wrinkles, measured by the facial wrinkle and elasticity scale (fwes), 3 months post-treatment. secondary outcomes include the global aesthetic improvement scale (gais) and a visual analog scale (vas) for pain. safety evaluations will include adverse event (ae) and serious adverse event (sae) monitoring.


Eligibility criteria:
inclusion criteria: 1. 18 to 65 years old（the date of signing the informed consent shall prevail）, gender is not limited. 2. facial and periorbital wrinkle and elasticity scale (fwes) score ≥ 3 points. both the facial and periorbital fwes should meet the criteria. 3. the subject fully understands the benefits and risks of this experiment, and is still willing to participate and sign the informed consent. exclusion criteria: 1. individuals with skin diseases, scars, open wounds, or metal implants in the area where clinical trial medical devices will be applied. 2. patients with implanted electrical devices (e.g., pacemakers, aicds). 3. those with a history of hypertrophic scars, keloids, or severe allergic reactions. 4. individuals with excessive facial fat requiring surgical treatment. 5. those with autoimmune diseases, acute viral herpes, or poorly controlled diabetes. 6. people with abnormal coagulation function or those taking anticoagulant medications (e.g., aspirin, warfarin) within 1 week of screening. 7. individuals treated with fillers or botulinum toxin within the last 6 months or permanent fillers in the treatment area. 8. those who have received skin treatments (e.g., deep exfoliation, lasers, light therapy) in the treatment area within 6 months. 9. pregnant or lactating women, or women of childbearing potential not using medically accepted contraception. 10. persons deemed inappropriate by the investigator to participate in this clinical trial.

Keywords: volnewmer facial skin treatment nasolabial folds marionette line mrf facial wrinkles wrinkles monopolar radiofrequency device
3-year observational virology follow-up study in subjects who participated in studies of idenix anti-hcv, direct acting antivirals

Conditions: Hepatitis C

Summary: all subjects in this study have previously been in an idenix hcv study and received study drug for 3 consecutive days. subjects who had received placebo in a previous idenix study will not be enrolled in this study. in this study, researchers will try to find answers to these questions: * how much (if any) hepatitis c virus is in your blood after stopping your idenix study drug? * is your hepatitis c virus possibly resistant to treatment with the idenix study drug or similar drugs?

the data obtained from this study will be used to further understand the long-term efficacy of idenix daas used to treat hcv infection and to further understand hcv resistance to idenix daas.

Eligibility criteria:
inclusion criteria: * read and signed the written informed consent form (icf) after the nature of the study has been fully explained * have participated in an idenix-sponsored study of an idenix daa * received at least 3 consecutive days of daa treatment in an idenix-sponsored study * agreed to comply with the visit schedule and laboratory tests exclusion criteria: * treatment with placebo only, in an idenix sponsored study * antiviral treatment for hcv after participation in an idenix sponsored study of an idenix daa

Keywords: hcv hepatitis c idx184 idx719
treatment and clinical outcomes among sle patients in pregnancy

Conditions: Systemic Lupus Erythematosus; Pregnancy Related

Summary: systemic lupus erythematosus (sle) is a kind of systemic autoimmune disease which can cause multiple organs and system damage, which often occurs in women of childbearing age. compared with healthy pregnant women, sle patients have higher incidence of premature delivery, preeclampsia and fetal loss during pregnancy. since sle patients usually have disease activity during pregnancy and postpartum, and a variety of maternal and fetal diseases are closely related to sle, it is very important to monitor the disease activity and drug treatment of sle patients during pregnancy.

objective: to study the risk factors of poor pregnancy outcomes in sle patients, and evaluate impact of different therapies on the maternal and fetal health. methods: our department and shanghai gothic network technology co., ltd. jointly established the chronic disease management of sle patients during pregnancy and lactation by using smart system of disease management#ssdm#. with this platform#patients in pregnancy can consult with rheumatologists face to face and follow-up regularly. follow-up: consultation and followup will be scheduled every 4 weeks from confirmed pregnancy until delivery.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with systemic lupus erythematosus (sle) (acr criteria, 1997); 2. pregnant women aged 20-45 years old; 3. willing to participate in this study, willing to medication and follow-up according to the treatment plan, and sign the informed consent. exclusion criteria: 1. the cause of previous abortion was known: * known chromosomal abnormalities in the parent, maternal or embryo. - page 3 of 4 \[draft\] -• endocrine dysfunction of pregnant women: luteal dysfunction; polycystic ovarian syndrome; ovarian premature failure (fsh ≥ 20uu/ l) in follicular stage; * hyperprolactinemia thyroid disease; other hypothalamic pituitary adrenal axis abnormalities in diabetes mellitus. * abnormal anatomy of pregnant women: abnormal uterus; asherman syndrome; the uterine fibrosis of cervical insufficiency is more than 5 cm. vaginal infection. * any known serious heart disease, liver, kidney, blood or endocrine disease. 2. any active infection active viral hepatitis includes hepatitis b virus (hbv), hepatitis c virus (hcv), human papillomavirus (hpv). active infections include small intestine herpes zoster virus (vzv), human immunodeficiency virus (hiv), syphilis or tuberculosis. 3. allergic to prednisone, hydroxychloroquine, low molecular weight heparin or aspirin. 4. the history of the disease is as follows: * there was a history of peptic ulcer or upper gastrointestinal bleeding in the past. * the past history of malignant tumor. * the past history of epilepsy or psychosis. 5. women who disagree or cannot complete the follow-up during pregnancy and after delivery.

Keywords: systemic lupus erythematosus pregnancy related clinical features risk factors
pilot study to evaluate the efficacy of zidovudine in preventing cd4+ lymphocyte decline in patients with primary hiv infection. (one treatment arm receives placebo)

Conditions: HIV Infections

Summary: to evaluate the safety and efficacy of early treatment with zidovudine for preventing a decline in cd4+ lymphocyte counts in patients with primary hiv infection. to determine the natural history of virologic and immunologic changes in primary hiv infection. previous studies indicate that intervention with zidovudine during primary hiv infection could reduce the initial viral burden and subsequent decline in immune functions, and could prolong not only the time to development of aids but also the time to initiation of chronic antiretroviral therapy.

previous studies indicate that intervention with zidovudine during primary hiv infection could reduce the initial viral burden and subsequent decline in immune functions, and could prolong not only the time to development of aids but also the time to initiation of chronic antiretroviral therapy. patients are randomized to receive either zidovudine or placebo daily for 24 weeks. patients are followed until development of an aids-related opportunistic infection or malignancy. after week 24, patients meeting standard prescribing criteria may start fda-approved anti-hiv therapies. after study week 48, patients may co-enroll on another clinical trial to receive experimental therapy.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * medications for nausea, vomiting, analgesia, or anxiety. patients must have: * asymptomatic or symptomatic primary hiv infection, plus one of the following two criteria: 1. p24 antigenemia documented within 1 month prior to study entry and either hiv enzyme immunoassay (ia) negative or hiv ia positive with western blot negative/indeterminate, within 1 month prior to study entry. 2. documented seroconversion within 1 month prior to study entry and western blot negative/indeterminate. * consent of parent or guardian if less than 18 years of age. exclusion criteria co-existing condition: patients with the following condition are excluded: * poor venous access. concurrent medication: excluded: * chronic steroid use. * immunomodulators. * myelosuppressive agents. * other antiretroviral agents or experimental therapies (note: fda-approved therapies permitted in patients who qualify after week 24; experimental therapies permitted after study week 48).

Keywords: zidovudine
perioperative analgesia modes in minimally invasive esophagectomy

Conditions: Esophageal Cancer; Perioperative Analgesia; NSAIDs; Opioid; Patient-controlled Analgesia

Summary: this study was designed to compare analgesic efficacy and safety of different perioperative analgesic modes in minimally invasive esophagectomy for esophageal cancer.


Eligibility criteria:
inclusion criteria: * 18-75 years; * patients underwent laparoscopic and thoracoscopic or robotic-assisted minimally invasive esophagectomy ; * informed consent. exclusion criteria: * has a history of cholecystitis or urolithiasis within 3 months; * has a history of atherothrombosis (peripheral arterial disease), stroke, myocardial infarction; * with lung diseases, such as pneumonia, atelectasis, emphysema, pulmonary bullae, etc; * preoperative cardiac function grade ≥ iii or coronary artery stenosis; * preoperative indwelling of a thoracic drainage tube; * long-term heavy drinker(heavy drinking was defined as follows: for men, consuming more than 4 drinks on any day or more than 14 drinks per week; for women, consuming more than 3 drinks on any day or more than 7 drinks per week); * opioid-tolerant patients(defined as those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid); * with painful skin complications, such as rashes and blisters; * conversion to open surgery; * the postoperative ventilation function was limited, or the duration of endotracheal intubation was more than 24h.